Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 3.5× uniQure N.V. Ordinary Shares's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ORKA | QURE | |
|---|---|---|
Market Cap | $5.18B | $1.48B |
Volume | 490,798 | 2,488,780 |
Sector | Health | Health |
52-Week High | $113.08 | $70.59 |
52-Week Low | $26.19 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.31B | $728.62M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
